HK Stock Market Move | AKESO (09926) rose more than 5% in early trading. Institutions are still optimistic about ivonescimab beating K medicine.

AKESO (09926) rose by more than 5% in the early session, with a 5.48% increase to HK$134.8 by the time of reporting, with a trading volume of HK$5.55 billion. On the news front, on April 30th, AKESO's partner Summit Therapeutics disclosed that the Phase III HARMONi-3 study of the PD-1/VEGF dual antibody ivonescimab did not achieve the planned interim progression-free survival (PFS) results. CITIC SEC (Hong Kong) stated that the study indicated that the unexpected results only reflected ivonescimab's inability to significantly surpass Keytruda in the midterm stage under strict preset conditions. The analysis emphasized that based on the experience of HARMONi-6, it is expected that with normal and more lenient alpha distribution in the second half of 2026, the drug is confident in beating Keytruda in HARMONi-3.